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There is now a large body of evidence describing the significant risk of obesity and 
metabolic complications in the children of mothers who were over-weight or obese 
during pregnancy (Zou et al., 2016). As rates of maternal obesity increase across 
many populations, an urgent need has arisen for clinically applicable strategies to help 
prevent obesity from being perpetuated across generations. However, despite a 
number of trials of various antioxidant and other compounds in animal models, few 
interventions hold significant translational promise. 
 
The paper by Zou et al., in this issue of The Journal of Physiology, demonstrates 
using a high-fat maternal diet mouse model that supplementation with resveratrol 
during pregnancy improves insulin sensitivity and reduces obesity in high-fat fed 
offspring (Zou et al., 2016). These striking findings suggest that resveratrol 
supplementation to obese mothers has beneficial effects in the offspring, at least in 
part by altering the composition of offspring adipose tissue from white to beige. The 
metabolic benefits of such a transition are well established, leading to enhanced 
ability to dissipate excess energy as heat rather than storing it as lipid. Not only were 
molecular endpoints and the composition of adipocytes in offspring demonstrably 
changed when resveratrol was added as a maternal supplement, but there were also 
improvements in important downstream clinical endpoints. In particular, the offspring 
whose mothers had received resveratrol supplementation during pregnancy had 
reduced weight gain and improved insulin sensitivity in adulthood even when fed a 
high-fat diet.  
 
As with other polyphenol dietary supplements that have been suggested as 
translatable interventions, there are a number of considerations that must be carefully 
evaluated prior to a trial in human pregnancy. The primary concern with any 
supplement or pharmacological agent in pregnancy is a full evaluation for any 
possibility of teratogenicity or adverse impact on fetal development and immediate 
pregnancy outcome. Reports have suggested that resveratrol may be detrimental to 
normal fetal adrenal development (Savchuk et al., 2016), which could have potential 
long-term consequences for steroidogenesis in offspring. If such an effect occurs in 
human pregnancy then this is likely to rule out resveratrol as a beneficial intervention. 
The second issue relates to bioavailability in humans, both in the maternal circulation 
and its ability to cross the placenta. While studies suggest that resveratrol can move 
across the placental barrier and into cells, it is relatively insoluble in water (Balata et 
al., 2016). This creates challenges in achieving high enough plasma concentrations of 
resveratrol in the mother to make it available to the fetus. If the beneficial effects of 
resveratrol are direct effects on the fetus, then this is an important issue. However, if 
the offspring effects of resveratrol are mediated via its effects on the maternal 
metabolic milieu, then lower plasma concentrations may still be effective. The 
relative contributions of these two mechanisms should be evaluated in the future, 
potentially by measuring transplacental resveratrol concentrations, or by direct fetal 
catheterization. Other considerations include efficacy within a safe and feasible 
dosing range. Resveratrol doses previously trialed in human subjects lie in the 20-
50mg/kg/day range (Gambini et al., 2013), whereas the study of Zou et al. used a dose 
of 200mg/kg/day in the rodent (which may be accounted for by relatively high 
metabolic rates). This raises the important question of whether the beneficial 
offspring effects reported by Zou et al. would still occur at the lower doses suitable 
for human consumption. 
 
An under-reported and widely ignored aspect of the perpetuation of obesity through 
generations is the direct impact of maternal obesity on the social aspects of child 
development. A key positive feature of resveratrol supplementation in pregnancy as 
reported by Zou et al., is that it promotes postpartum weight loss, reduces adipose 
tissue mass, and increases insulin sensitivity in the obese mother. The positive role-
modeling from a mother whose weight and eating behaviour are within the normal 
range may itself be protective against offspring obesity (Thompson, 2013). This 
aspect is particularly important when considering the translational implications in 
humans, where learned aspects of eating, appetite, and exercise patterns are prominent 
in childhood development. Furthermore, resveratrol supplementation to obese 
mothers during pregnancy increases postpartum weight loss and hence is likely to 
reduce inter-pregnancy weight gain. Maternal resveratrol may thus be of benefit not 
only to the fetus of the index pregnancy but also potentially to future offspring, via a 
reduced likelihood of pregnancy complications associated with maternal obesity.  
 
In future studies it will be important to address whether the beneficial effects of 
maternal resveratrol supplementation are limited to situations of obese pregnancy or if 
it would be effective in mitigating the risks of other adverse exposures during 
pregnancy, for example other dietary manipulations, chronic hypoxia and increased 
stress. There are very limited data regarding whether ‘natural’ dietary 
supplementation with resveratrol could be sufficient to ensure high enough 
concentrations of the bioactive compound. Furthermore, the gestational window 
during which resveratrol supplementation would be of benefit is not clear from 
available data. It will be particularly important to define the potential window of 
opportunity to improve offspring outcome using resveratrol if it extends beyond the 
pregnancy period. An ideal intervention to break the intergenerational cycle of obesity 
may be one that is not only effective as a maternal supplement during pregnancy but 
one that could also be applied during neonatal life if the initial window of opportunity 
was missed. Further studies will be required to establish if resveratrol represents such 
an intervention. 
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